Press Release Details

Cerus Corporation to Webcast Fourth Quarter and Year-End Financial Results Conference Call

February, 02 2006

CONCORD, Calif.--(BUSINESS WIRE)--Feb. 2, 2006--In conjunction with Cerus Corporation's (Nasdaq:CERS) report of its fourth quarter and year-end financial results, a live webcast will be made of its conference call hosted by Claes Glassell, president and CEO, William J. Dawson, vice president, finance and CFO, David N. Cook, vice president, research and development and Dr. Larry Corash, chief medical officer.

What:      Financial results, with an update on progress and future

When:      Friday, February 24, 2006 at 4:30 p.m. ET


Contact:   Ruey-Li Hwang / Cerus Corporation, 925-288-6017

Cerus Corporation's fourth quarter and year-end release will be issued on February 24, 2006 at 4:00 p.m. EDT and will be made available at The company will archive the earnings release audio replay as well as the press release on the company's website.

The conference call is protected by copyright. It cannot be recorded or rebroadcast without Cerus' permission.


Cerus Corporation is developing novel products for cancer, infectious disease and blood safety based on multiple, innovative technology platforms. The company is building a pipeline of next generation cancer immunotherapies by combining its proprietary attenuated Listeria vector platform with promising disease antigens. These products are designed to stimulate innate and T cell immune pathways, generating highly potent anti-tumor responses. The company's KBMA vaccine technology has potential broad applications against multiple pathogens. Cerus is applying its Helinx technology to develop the INTERCEPT Blood System, which is designed to enhance the safety of blood components through pathogen inactivation. The company's strategy is to leverage the broad potential of its technologies and products both on its own and through alliances. Cerus' partners to date include MedImmune and investigators at The Johns Hopkins University for cancer immunotherapy, and Baxter International and BioOne for the INTERCEPT Blood System.

Helinx is a trademark of Cerus Corporation.

Baxter and INTERCEPT are trademarks of Baxter International Inc.

    CONTACT: Cerus Corporation
             Ruey-Li Hwang, 925-288-6017

    SOURCE: Cerus Corporation

    Global Headquarters

  • 1220 Concord Avenue
  • Concord, CA US 94520
  • +1 925.288.6000

    European Headquarters

  • Stationsstraat 79-D
  • 3811 MH Amersfoort, Netherlands
  • +31 (0) 33 49 60 600